PMID- 16372244
OWN - NLM
STAT- MEDLINE
DCOM- 20060404
LR  - 20220409
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 21
IP  - 3
DP  - 2006 Mar
TI  - HER-2 status determination in breast carcinomas. A practical approach.
PG  - 227-36
LID - 10.14670/HH-21.227 [doi]
AB  - Accurate evaluation of HER-2 status is crucial in the selection of breast 
      carcinoma patients for trastuzumab (Herceptin) treatment. Various laboratory 
      methods have been used for this purpose. The aim of the present work was to 
      analyse the results obtained in the routine practice by immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH) in determination of HER-2 
      status. Five hundred and three cases of breast invasive ductal carcinoma were 
      selected to analyse the HER-2 overexpression by immunohistochemistry (HercepTest, 
      Dako). HercepTest 2+ equivocal cases (60) were studied by FISH (PathVysion, 
      Vysis) to determine HER-2 gene amplification. HER-2 overexpression determined by 
      Herceptest was shown in 97/503 cases (19%). FISH performed on equivocal cases 
      demonstrated HER-2 amplification in 11/60 tumours (18%). IHC and FISH together 
      showed HER-2 overexpression/gene amplification in 21% of breast invasive 
      carcinomas. Immunohistochemical determination of HER-2 status represents an easy 
      and standardized method that (in contrast to FISH) can be performed in all 
      pathology laboratories without need of any special microscope and enabling to 
      check the morphologic features of the cells analysed. However, in order to assure 
      the reliability of the results, standardization of fixation protocols, automation 
      of the immunohistochemical procedure, and training of pathologists in the 
      interpretation of the results (scoring criteria) should be a priority. Equivocal 
      HercepTest cases must be analysed by FISH preferably in a reference laboratory.
FAU - Garcia-Caballero, T
AU  - Garcia-Caballero T
AD  - Department of Morphological Sciences, Faculty of Medicine, University Clinical 
      Hospital of Santiago de Compostela, Spain. cm-tgc@usc.es
FAU - Menendez, M D
AU  - Menendez MD
FAU - Vazquez-Boquete, A
AU  - Vazquez-Boquete A
FAU - Gallego, R
AU  - Gallego R
FAU - Forteza, J
AU  - Forteza J
FAU - Fraga, M
AU  - Fraga M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Breast Neoplasms/*chemistry/drug therapy/genetics
MH  - Carcinoma, Ductal, Breast/*chemistry/drug therapy/genetics
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Genes, erbB-2/genetics
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Reproducibility of Results
MH  - Trastuzumab
EDAT- 2005/12/24 09:00
MHDA- 2006/04/06 09:00
CRDT- 2005/12/24 09:00
PHST- 2005/12/24 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2005/12/24 09:00 [entrez]
AID - 10.14670/HH-21.227 [doi]
PST - ppublish
SO  - Histol Histopathol. 2006 Mar;21(3):227-36. doi: 10.14670/HH-21.227.